Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference
Rhea-AI Summary
Repligen (NASDAQ:RGEN) will present at the Bank of America Securities 2026 Global Healthcare Conference in Las Vegas on May 12-14, 2026. CFO Jason Garland will take part in an analyst-led discussion on May 12 at 10:00am PT.
A live webcast will be available on Repligen's Investor Relations website with a limited-time replay following the event.
Positive
- None.
Negative
- None.
News Market Reaction – RGEN
In the May 7 session, RGEN gained 0.53%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 05 | Q1 2026 earnings | Positive | +6.3% | Revenue growth and raised adjusted EPS guidance with strong cash position. |
| Apr 22 | Earnings date notice | Neutral | -5.0% | Scheduling announcement for Q1 2026 results and conference call details. |
| Apr 17 | Facility expansion | Positive | +3.2% | Opening European Training & Innovation Center to expand customer support. |
| Mar 05 | Conference participation | Neutral | -0.6% | Planned participation in three March 2026 investor conferences. |
| Feb 24 | FY2025 earnings | Positive | -0.5% | Strong 2025 revenue growth and 2026 guidance with margin expansion targets. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings and operational expansion headlines often saw positive or modestly positive reactions, while some guidance and scheduling updates produced flat-to-negative moves.
Over the last few months, Repligen reported multiple financial and strategic updates. Q1 2026 results on May 5 drove a 6.26% gain after revenue growth and raised EPS guidance. Prior earnings on Feb 24 highlighted strong 2025 growth and 2026 guidance but saw a slight share decline. Operational news such as the Breda Training & Innovation Center opening on Apr 17 led to a 3.24% rise. Announcements about conference participation, like the March 2026 events, drew minimal price impact. Today’s Bank of America conference appearance fits that non-fundamental pattern.
Key Terms
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Bank of America Securities 2026 Global Healthcare Conference, being held May 12-14 in Las Vegas, Nevada. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on May 12 at 10:00am PT.
A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the Company see our website at www.repligen.com, and follow us on LinkedIn.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com
